인유두종바이러스 백신 시장(적응증: 자궁경부암, 항문암, 질암, 음경암, 외음부암, 중인두암, 생식기 사마귀, 기타) : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Human Papillomavirus Vaccine Market - Scope of Report

TMR's report on the global human papillomavirus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global human papillomavirus vaccine market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global human papillomavirus vaccine market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the human papillomavirus vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global human papillomavirus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global human papillomavirus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global human papillomavirus vaccine market.

The report delves into the competitive landscape of the global human papillomavirus vaccine market. Key players operating in the global human papillomavirus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global human papillomavirus vaccine market profiled in this report.

Key Questions Answered in Global human papillomavirus vaccine Market Report:

• What is the sales/revenue generated by human papillomavirus vaccine across all regions during the forecast period?
• What are the opportunities in the global human papillomavirus vaccine market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Human Papillomavirus Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global human papillomavirus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global human papillomavirus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global human papillomavirus vaccine market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Papillomavirus Vaccine Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Human Papillomavirus Vaccine Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Valence, 2017-2031
  • 6.3.1. Bivalent
  • 6.3.2. Quadrivalent and Nonavalent
• 6.4. Market Attractiveness Analysis, by Valence

7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Indication, 2017-2031
  • 7.3.1. Cervical Cancer
  • 7.3.2. Anal Cancer
  • 7.3.3. Vaginal Cancer
  • 7.3.4. Penile Cancer
  • 7.3.5. Vulvar Cancer
  • 7.3.6. Oropharyngeal Cancer
  • 7.3.7. Genital Warts
  • 7.3.8. Others
• 7.4. Market Attractiveness Analysis, by Indication

8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 8.3.1. Physicians
  • 8.3.2. Wholesalers
  • 8.3.3. Physician Distributors
  • 8.3.4. Government Entities
  • 8.3.5. Public and Private Alliances
• 8.4. Market Attractiveness Analysis, by Indication

9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2017-2031
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Human Papillomavirus Vaccine Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Valence, 2017-2031
  • 10.3.1. Bivalent
  • 10.3.2. Quadrivalent and Nonavalent
• 10.4. Market Value Forecast, by Indication, 2017-2031
  • 10.4.1. Cervical Cancer
  • 10.4.2. Anal Cancer
  • 10.4.3. Vaginal Cancer
  • 10.4.4. Penile Cancer
  • 10.4.5. Vulvar Cancer
  • 10.4.6. Oropharyngeal Cancer
  • 10.4.7. Genital Warts
  • 10.4.8. Others
• 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.5.1. Physicians
  • 10.5.2. Wholesalers
  • 10.5.3. Physician Distributors
  • 10.5.4. Government Entities
  • 10.5.5. Public and Private Alliances
• 10.6. Market Value Forecast, by Country, 2017-2031
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Valence
  • 10.7.2. By Indication
  • 10.7.3. By Distribution Channel
  • 10.7.4. By Country

11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Valence, 2017-2031
  • 11.3.1. Bivalent
  • 11.3.2. Quadrivalent and Nonavalent
• 11.4. Market Value Forecast, by Indication, 2017-2031
  • 11.4.1. Cervical Cancer
  • 11.4.2. Anal Cancer
  • 11.4.3. Vaginal Cancer
  • 11.4.4. Penile Cancer
  • 11.4.5. Vulvar Cancer
  • 11.4.6. Oropharyngeal Cancer
  • 11.4.7. Genital Warts
  • 11.4.8. Others
• 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.5.1. Physicians
  • 11.5.2. Wholesalers
  • 11.5.3. Physician Distributors
  • 11.5.4. Government Entities
  • 11.5.5. Public and Private Alliances
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Valence
  • 11.7.2. By Indication
  • 11.7.3. By Distribution Channel
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Valence, 2017-2031
  • 12.3.1. Bivalent
  • 12.3.2. Quadrivalent and Nonavalent
• 12.4. Market Value Forecast, by Indication, 2017-2031
  • 12.4.1. Cervical Cancer
  • 12.4.2. Anal Cancer
  • 12.4.3. Vaginal Cancer
  • 12.4.4. Penile Cancer
  • 12.4.5. Vulvar Cancer
  • 12.4.6. Oropharyngeal Cancer
  • 12.4.7. Genital Warts
  • 12.4.8. Others
• 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.5.1. Physicians
  • 12.5.2. Wholesalers
  • 12.5.3. Physician Distributors
  • 12.5.4. Government Entities
  • 12.5.5. Public and Private Alliances
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Valence
  • 12.7.2. By Indication
  • 12.7.3. By Distribution Channel
  • 12.7.4. By Country/Sub-region

13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Valence, 2017-2031
  • 13.3.1. Bivalent
  • 13.3.2. Quadrivalent and Nonavalent
• 13.4. Market Value Forecast, by Indication, 2017-2031
  • 13.4.1. Cervical Cancer
  • 13.4.2. Anal Cancer
  • 13.4.3. Vaginal Cancer
  • 13.4.4. Penile Cancer
  • 13.4.5. Vulvar Cancer
  • 13.4.6. Oropharyngeal Cancer
  • 13.4.7. Genital Warts
  • 13.4.8. Others
• 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.5.1. Physicians
  • 13.5.2. Wholesalers
  • 13.5.3. Physician Distributors
  • 13.5.4. Government Entities
  • 13.5.5. Public and Private Alliances
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Valence
  • 13.7.2. By Indication
  • 13.7.3. By Distribution Channel
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Valence, 2017-2031
  • 14.3.1. Bivalent
  • 14.3.2. Quadrivalent and Nonavalent
• 14.4. Market Value Forecast, by Indication, 2017-2031
  • 14.4.1. Cervical Cancer
  • 14.4.2. Anal Cancer
  • 14.4.3. Vaginal Cancer
  • 14.4.4. Penile Cancer
  • 14.4.5. Vulvar Cancer
  • 14.4.6. Oropharyngeal Cancer
  • 14.4.7. Genital Warts
  • 14.4.8. Others
• 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.5.1. Physicians
  • 14.5.2. Wholesalers
  • 14.5.3. Physician Distributors
  • 14.5.4. Government Entities
  • 14.5.5. Public and Private Alliances
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Valence
  • 14.7.2. By Indication
  • 14.7.3. By Distribution Channel
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. Merck & Co., Inc.
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. GlaxoSmithKline plc
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Sanofi
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. AstraZeneca
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Serum Institute of India Pvt. Ltd.
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Xiame Innovax Biotech Co., Ltd.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. General Incorporated Foundation
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Bharat Biotechare
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. SWOT Analysis
    • 15.3.9.4. Financial Overview
    • 15.3.9.5. Strategic Overview